Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects with severe hemophilia A (documented plasma baseline Factor VIII level \<1 %)~* \>/= 18 but \</= 65 years of age~* Previously treated with Factor VIII concentrate(s) for a minimum of 150 exposure days (as supported by the subject's medical history)~* Immunocompetent with a CD4+ lymphocyte count \> 400/mm³~* Signed informed consent from subject~Exclusion Criteria:~* Documented history of inhibitor to Factor VIII with a titer \>/= 0.6 BU (Biological Unit), by the Nijmegen modified assay. However, subjects with a maximum historical titer of \</= 1.0 BU with the classical Bethesda assay on a single measurement but with at least 3 subsequent successive negative results (\< 0.6 BU) thereafter are eligible.~* Unable to stop Factor VIII treatment to complete a minimum 72 hour washout~* Current evidence of inhibitor to Factor VIII with a titer \>/= 0.6 BU, measured at the time of screening~* Abnormal renal function (serum creatinine \> 1.5 times the upper limit of the normal range)~* Total bilirubin \> 1.5 times the upper limit of the normal range~* Active hepatic disease (alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels \> 2 times the upper limit of the normal range)~* Any concomitant coagulation disorder other than hemophilia A (including lupus anticoagulant)~* Platelet count \< 100,000/mm³~* Within the last 3 months prior to study entry or during the study will be treated with an immunomodulating drug other than anti-retroviral chemotherapy (e.g., a interferon, steroids, rituximab, etc)~* Any subject who requires major surgery during study period. Minor procedures may be approved if discussed in advance with the medical expert.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).